BiotechTube

Eltrombopag + IVIG infusion

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Immune Thrombocytopenic Purpura

Conditions

Immune Thrombocytopenic Purpura

Trial Timeline

Oct 1, 2012 → Aug 1, 2019

NCT ID
NCT01621204

About Eltrombopag + IVIG infusion

Eltrombopag + IVIG infusion is a phase 3 stage product being developed by Novartis for Immune Thrombocytopenic Purpura. The current trial status is completed. This product is registered under clinical trial identifier NCT01621204. Target conditions include Immune Thrombocytopenic Purpura.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01621204Phase 3Completed

Competing Products

20 competing products in Immune Thrombocytopenic Purpura

See all competitors
ProductCompanyStageHype Score
Pirtobrutinib + PlaceboEli LillyPhase 1/2
41
Anti-(integrin beta-3) human monoclonal antibodyRallybioPhase 2
44
SatralizumabChugai PharmaceuticalPhase 3
77
Placebo + LusutrombopagShionogiPhase 2
52
LusutrombopagShionogiPhase 2
52
RomiplostimKyowa KirinPhase 1/2
41
AMG 531Kyowa KirinPhase 2/3
65
Romiplostim + PlaceboKyowa KirinPhase 3
77
Romiplostim (AMG-531)Kyowa KirinPhase 2
52
Romiplostim and danazolKyowa KirinPhase 2
52
Hetrombopag OlamineJiangsu Hengrui MedicinePhase 1
33
SHR0302 quick release tablets + SHR0302 sustained-release tabletsJiangsu Hengrui MedicinePhase 1
33
Hetrombopag + PlaceboJiangsu Hengrui MedicinePhase 3
77
HR19042 Capsule, Tarpeyo®, Budenofalk®Jiangsu Hengrui MedicinePhase 1
33
HR19042 CapsulesJiangsu Hengrui MedicinePhase 2
52
HerombopagJiangsu Hengrui MedicinePhase 3
77
Zostavax®MerckPre-clinical
23
Raltegravir + AtazanavirMerckPre-clinical
23
ZostavaxMerckPre-clinical
23
MK-8723 + Matching PlaceboMerckPhase 1
33

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85